View the historical price chart for VERU to analyze trends and spot opportunities. Use our interactive chart to compare past performance and make informed decisions.
Yes, VERU stock appears to be a good buy in 2025 based on our comprehensive analysis.
Comprehensive analysis of whether VERU stock is a good investment in 2025, including growth drivers, valuation metrics, risk factors, and analyst recommendations.
VERU presents a mixed investment profile for 2025. The company shows strong growth drivers including moderate revenue growth of 3.6%, though analyst price targets suggest 575.4% upside potential.
Analyst sentiment is generally positive with 8 buy ratings vs 1 sell ratings.
Investors should weigh the growth potential against the identified risks, particularly high debt-to-equity ratio of 16.10, and consider their own risk tolerance and investment timeline.
Based on our comprehensive analysis of VERU's financial metrics, growth prospects, valuation, analyst sentiment, and risk factors, we recommend a BUY. This recommendation considers the company's current fundamentals, market position, and future growth potential while accounting for identified risks and market conditions.
Analyze financial statements and market position
Review price charts and technical indicators
Evaluate market and company-specific risks
Healthcare
Biotechnology
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS)....
Make buy/hold/sell decision with price targets
Get detailed step-by-step analysis, risk assessment, and investment strategies
2916 North Miami Avenue, Miami, FL 33127
United States
Get detailed executive information, governance metrics, and comprehensive corporate data